Empagliflozin treatment for 3 months in patients with diabetes mellitus significantly improved left ventricular global longitudinal strain (-19.15 vs -17.71; p<0.001) and MME efficiency.
Observational (n=62)
Does empagliflozin improve left ventricular global longitudinal strain and myocardial mechano-energetic efficiency in patients with diabetes mellitus without cardiovascular disease?
Empagliflozin significantly improves subclinical echocardiographic markers of left ventricular pump efficiency and contraction (GLS and MME) in diabetic patients without established cardiovascular disease.
p-value: p=<0.001
PURPOSE: Sodium glucose transporter-2 (SGLT-2) inhibitors are employed in the treatment of cardiovascular diseases such as heart failure and coronary artery disease. In the present study, we aimed to investigate how Empagliflozin in SGLT 2 inhibitors affects cardiac contraction and pump efficiency in patients who have Diabetes Mellitus (DM) without cardiovascular disease. METHODS: The conventional echocardiographic records and biochemical values of 62 patients who had DM without a history of cardiovascular disease were evaluated before using Empagliflozin. The myocardial mechano-energetic (MME) activity and index, and global longitudinal strain (GLS) were also calculated. After 3 months of Empagliflozin use, the tests were repeated and compared with previous data. A p < .05 was considered statistically significant. RESULTS: Left ventricular GLS and MME efficiency were found to be significantly higher after treatment (-17.71 ± 2.12, -19.15 ± .71; p < .001 and 62.14 ± 18.21, 72.24 ± 26.57; p: .019). CONCLUSION: An increase was detected in left ventricular longitudinal strain and MME efficiency after using Empagliflozin for 3 months in patients with DM. This result suggests that Empagliflozin improves left ventricular pump efficiency and contraction.
Dural et al. (Qui,) conduziram um estudo observacional em Diabetes Mellitus sem doença cardiovascular (n=62). Empagliflozina vs. Baseline (antes do tratamento) foi avaliada na deformação longitudinal global do ventrículo esquerdo (GLS) e na eficiência mecano-energética do miocárdio (MME) (p=<0.001). O tratamento com empagliflozina por 3 meses em pacientes com diabetes mellitus melhorou significativamente a deformação longitudinal global do ventrículo esquerdo (-19,15 vs -17,71; p<0,001) e a eficiência MME.